O	0	7	Quality
O	8	10	of
O	11	15	Life
O	16	18	of
O	19	24	Women
O	25	30	After
O	31	32	a
O	33	38	First
O	39	48	Diagnosis
O	49	51	of
O	52	58	Breast
O	59	65	Cancer
O	66	71	Using
O	72	73	a
B-intervention	74	78	Self
I-intervention	78	79	-
I-intervention	79	89	Management
I-intervention	90	97	Support
I-intervention	98	105	mHealth
I-intervention	106	109	App
O	110	112	in
B-location	113	119	Taiwan
O	119	120	:
O	121	131	Randomized
O	132	142	Controlled
O	143	148	Trial
O	148	149	.

O	150	155	There
O	156	159	are
O	160	164	over
O	165	166	2
O	167	174	million
O	175	180	newly
O	181	190	diagnosed
O	191	199	patients
O	200	204	with
O	205	211	breast
O	212	218	cancer
O	219	228	worldwide
O	229	233	with
O	234	238	more
O	239	243	than
O	244	246	10
O	246	247	,
O	247	250	000
O	251	256	cases
O	257	259	in
O	260	266	Taiwan
O	267	271	each
O	272	276	year
O	276	277	.

O	278	284	During
O	285	289	2017
O	289	290	-
O	290	294	2018
O	294	295	,
O	296	299	the
O	300	308	National
O	309	313	Yang
O	313	314	-
O	314	318	Ming
O	319	329	University
O	329	330	,
O	331	334	the
O	335	341	Taiwan
O	342	352	University
O	353	355	of
O	356	363	Science
O	364	367	and
O	368	378	Technology
O	378	379	,
O	380	383	and
O	384	387	the
O	388	394	Taiwan
O	395	401	Breast
O	402	408	Cancer
O	409	419	Prevention
O	420	430	Foundation
O	431	443	collaborated
O	444	446	to
O	447	454	develop
O	455	456	a
O	457	463	breast
O	464	470	cancer
O	471	475	self
O	475	476	-
O	476	486	management
O	487	494	support
O	495	496	(
O	496	501	BCSMS
O	501	502	)
O	503	510	mHealth
O	511	514	app
O	515	518	for
B-ethinicity	519	528	Taiwanese
O	529	534	women
O	535	539	with
O	540	546	breast
O	547	553	cancer
O	553	554	.

O	555	558	The
O	559	562	aim
O	563	565	of
O	566	570	this
O	571	576	study
O	577	580	was
O	581	583	to
O	584	595	investigate
O	596	599	the
O	600	607	quality
O	608	610	of
O	611	615	life
O	616	617	(
O	617	620	QoL
O	620	621	)
O	622	624	of
O	625	630	women
O	631	635	with
O	636	642	breast
O	643	649	cancer
O	650	652	in
O	653	659	Taiwan
O	660	665	after
O	666	671	using
O	672	675	the
O	676	681	BCSMS
O	682	685	app
O	685	686	.

O	687	692	After
O	693	702	receiving
O	703	704	a
O	705	710	first
O	711	720	diagnosis
O	721	723	of
O	724	730	breast
O	731	737	cancer
O	737	738	,
B-eligibility	739	744	women
I-eligibility	745	749	with
I-eligibility	750	755	stage
I-eligibility	756	757	0
I-eligibility	758	760	to
I-eligibility	761	764	III
I-eligibility	765	771	breast
I-eligibility	772	778	cancer
I-eligibility	778	779	,
I-eligibility	780	783	who
I-eligibility	784	788	were
I-eligibility	789	798	recruited
I-eligibility	799	803	from
I-eligibility	804	810	social
I-eligibility	811	821	networking
I-eligibility	822	827	sites
I-eligibility	828	830	or
I-eligibility	831	839	referred
I-eligibility	840	842	by
I-eligibility	843	848	their
I-eligibility	849	860	oncologists
I-eligibility	861	863	or
I-eligibility	864	872	oncology
I-eligibility	873	877	case
I-eligibility	878	886	managers
O	886	887	,
O	888	892	were
O	893	903	randomized
O	904	905	1
O	905	906	:
O	906	907	1
O	908	912	into
O	913	925	intervention
O	926	929	and
B-control	930	937	control
I-control	938	944	groups
O	944	945	.

O	946	958	Intervention
O	959	964	group
O	965	973	subjects
O	974	978	used
O	979	982	the
O	983	988	BCSMS
O	989	992	app
O	993	996	and
O	997	1000	the
O	1001	1008	control
O	1009	1014	group
O	1015	1023	subjects
O	1024	1032	received
B-control	1033	1038	usual
I-control	1039	1043	care
O	1043	1044	.

O	1045	1048	Two
O	1049	1063	questionnaires
O	1063	1064	-
O	1064	1067	the
O	1068	1076	European
O	1077	1089	Organization
O	1090	1093	for
O	1094	1102	Research
O	1103	1106	and
O	1107	1116	Treatment
O	1117	1119	of
O	1120	1126	Cancer
O	1127	1128	(
O	1128	1133	EORTC
O	1133	1134	)
O	1135	1142	Quality
O	1142	1143	-
O	1143	1145	of
O	1145	1146	-
O	1146	1150	Life
O	1151	1164	Questionnaire
O	1165	1169	Core
O	1170	1172	30
O	1173	1174	(
O	1174	1177	QLQ
O	1177	1178	-
O	1178	1181	C30
O	1181	1182	)
O	1183	1186	and
O	1187	1190	the
O	1191	1196	EORTC
O	1197	1203	Breast
O	1204	1210	Cancer
O	1210	1211	-
O	1211	1219	Specific
O	1220	1227	Quality
O	1227	1228	-
O	1228	1230	of
O	1230	1231	-
O	1231	1235	Life
O	1236	1249	Questionnaire
O	1250	1251	(
O	1251	1254	QLQ
O	1254	1255	-
O	1255	1259	BR23
O	1259	1260	)
O	1260	1261	-
O	1261	1265	were
O	1266	1277	distributed
O	1278	1280	to
O	1281	1289	subjects
O	1290	1292	in
O	1293	1297	both
O	1298	1302	arms
O	1302	1303	.

O	1304	1309	Paper
O	1309	1310	-
O	1310	1315	based
O	1316	1330	questionnaires
O	1331	1335	were
O	1336	1340	used
O	1341	1343	at
O	1344	1352	baseline
O	1352	1353	;
O	1354	1359	paper
O	1359	1360	-
O	1360	1365	based
O	1366	1368	or
O	1369	1372	Web
O	1372	1373	-
O	1373	1378	based
O	1379	1393	questionnaires
O	1394	1398	were
O	1399	1403	used
O	1404	1406	at
O	1407	1408	1
O	1408	1409	.
O	1409	1410	5
O	1410	1411	-
O	1411	1416	month
O	1417	1420	and
O	1421	1422	3
O	1422	1423	-
O	1423	1428	month
O	1429	1435	follow
O	1435	1436	-
O	1436	1438	up
O	1439	1450	evaluations
O	1450	1451	.

O	1452	1455	All
O	1456	1467	evaluations
O	1468	1472	were
O	1473	1477	self
O	1477	1478	-
O	1478	1486	assessed
O	1487	1490	and
O	1491	1500	anonymous
O	1500	1501	,
O	1502	1505	and
O	1506	1518	participants
O	1519	1523	were
O	1524	1531	blinded
O	1532	1534	to
O	1535	1540	their
O	1541	1551	allocation
O	1552	1558	groups
O	1558	1559	.

O	1560	1571	Descriptive
O	1572	1580	analysis
O	1580	1581	,
O	1582	1585	the
O	1586	1593	Pearson
O	1594	1597	chi
O	1597	1598	-
O	1598	1604	square
O	1605	1609	test
O	1609	1610	,
O	1611	1619	analysis
O	1620	1622	of
O	1623	1631	variance
O	1631	1632	,
O	1633	1636	and
O	1637	1640	the
O	1641	1652	generalized
O	1653	1663	estimating
O	1664	1672	equation
O	1673	1677	were
O	1678	1682	used
O	1683	1685	to
O	1686	1693	analyze
O	1694	1697	the
O	1698	1702	data
O	1702	1703	.

O	1704	1711	Missing
O	1712	1718	values
O	1718	1719	,
O	1720	1724	with
O	1725	1728	and
O	1729	1736	without
O	1737	1742	multi
O	1742	1743	-
O	1743	1753	imputation
O	1754	1764	techniques
O	1764	1765	,
O	1766	1770	were
O	1771	1775	used
O	1776	1779	for
O	1780	1791	sensitivity
O	1792	1800	analysis
O	1800	1801	.

O	1802	1803	A
O	1804	1809	total
O	1810	1812	of
B-total-participants	1813	1816	112
O	1817	1822	women
O	1823	1827	were
O	1828	1836	enrolled
O	1837	1840	and
O	1841	1849	randomly
O	1850	1859	allocated
O	1860	1862	to
O	1863	1869	either
O	1870	1873	the
O	1874	1886	experimental
O	1887	1892	group
O	1893	1894	(
O	1894	1895	n
O	1895	1896	=
B-intervention-participants	1896	1898	53
O	1898	1899	)
O	1900	1902	or
O	1903	1910	control
O	1911	1916	group
O	1917	1918	(
O	1918	1919	n
O	1919	1920	=
B-control-participants	1920	1922	59
O	1922	1923	)
O	1923	1924	.

O	1925	1928	The
O	1929	1935	follow
O	1935	1936	-
O	1936	1938	up
B-outcome	1939	1949	completion
I-outcome	1950	1954	rate
O	1955	1958	was
O	1959	1961	89
O	1961	1962	.
O	1962	1963	3
O	1963	1964	%
O	1965	1966	(
B-total-participants	1966	1969	100
O	1969	1970	/
O	1970	1973	112
O	1973	1974	)
O	1974	1975	.

O	1976	1979	The
O	1980	1991	demographic
O	1992	1996	data
O	1997	2003	showed
O	2004	2015	homogeneity
O	2016	2023	between
O	2024	2027	the
O	2028	2031	two
O	2032	2038	groups
O	2039	2041	in
O	2042	2045	age
O	2046	2047	(
O	2047	2052	range
O	2053	2055	50
O	2055	2056	-
O	2056	2058	64
O	2059	2064	years
O	2064	2065	)
O	2065	2066	,
O	2067	2073	breast
O	2074	2080	cancer
O	2081	2086	stage
O	2087	2088	(
O	2088	2093	stage
O	2094	2096	II
O	2096	2097	)
O	2097	2098	,
O	2099	2106	marital
O	2107	2113	status
O	2114	2115	(
O	2115	2122	married
O	2122	2123	)
O	2123	2124	,
O	2125	2132	working
O	2133	2139	status
O	2140	2141	(
O	2141	2149	employed
O	2149	2150	)
O	2150	2151	,
O	2152	2155	and
O	2156	2165	treatment
O	2166	2172	status
O	2173	2174	(
O	2174	2183	receiving
O	2184	2194	treatments
O	2194	2195	)
O	2195	2196	.

O	2197	2200	The
B-outcome	2201	2205	mean
I-outcome	2206	2211	total
I-outcome	2212	2215	QoL
I-outcome	2216	2223	summary
I-outcome	2224	2230	scores
O	2231	2235	from
O	2236	2239	the
B-outcome	2240	2243	QLQ
I-outcome	2243	2244	-
I-outcome	2244	2247	C30
O	2248	2249	(
B-iv-cont-mean	2249	2251	83
I-iv-cont-mean	2251	2252	.
I-iv-cont-mean	2252	2254	45
O	2255	2257	vs
B-cv-cont-mean	2258	2260	82
I-cv-cont-mean	2260	2261	.
I-cv-cont-mean	2261	2263	23
O	2263	2264	,
O	2265	2266	P
O	2266	2267	=
O	2267	2268	.
O	2268	2270	03
O	2270	2271	)
O	2272	2275	and
O	2276	2279	the
B-outcome	2280	2283	QLQ
I-outcome	2283	2284	-
I-outcome	2284	2288	BR23
O	2289	2290	(
B-iv-cont-mean	2290	2292	65
I-iv-cont-mean	2292	2293	.
I-iv-cont-mean	2293	2295	53
O	2296	2298	vs
B-cv-cont-mean	2299	2301	63
I-cv-cont-mean	2301	2302	.
I-cv-cont-mean	2302	2304	13
O	2304	2305	,
O	2306	2307	P
O	2307	2308	=
O	2308	2309	.
O	2309	2311	04
O	2311	2312	)
O	2313	2317	were
O	2318	2331	significantly
O	2332	2338	higher
O	2339	2344	among
O	2345	2348	the
O	2349	2361	experimental
O	2362	2367	group
O	2368	2374	versus
O	2375	2378	the
O	2379	2386	control
O	2387	2392	group
O	2392	2393	,
O	2394	2406	respectively
O	2406	2407	,
O	2408	2410	at
O	2411	2412	3
O	2413	2419	months
O	2419	2420	.

O	2421	2425	This
O	2426	2434	research
O	2435	2443	provides
O	2444	2451	support
O	2452	2455	for
O	2456	2461	using
O	2462	2463	a
O	2464	2470	mobile
O	2471	2477	health
O	2478	2482	care
O	2483	2486	app
O	2487	2489	to
O	2490	2497	promote
O	2498	2501	the
O	2502	2505	QoL
O	2506	2511	among
O	2512	2517	women
O	2518	2520	in
O	2521	2527	Taiwan
O	2528	2533	after
O	2534	2535	a
O	2536	2541	first
O	2542	2551	diagnosis
O	2552	2554	of
O	2555	2561	breast
O	2562	2568	cancer
O	2568	2569	.

O	2570	2573	The
O	2574	2579	BCSMS
O	2580	2583	app
O	2584	2589	could
O	2590	2592	be
O	2593	2597	used
O	2598	2600	to
O	2601	2608	support
O	2609	2616	disease
O	2617	2621	self
O	2621	2622	-
O	2622	2632	management
O	2632	2633	,
O	2634	2637	and
O	2638	2645	further
O	2646	2656	evaluation
O	2657	2659	of
O	2660	2667	whether
O	2668	2671	QoL
O	2672	2674	is
O	2675	2684	sustained
O	2685	2687	is
O	2688	2697	warranted
O	2697	2698	.

O	2699	2713	ClinicalTrials
O	2713	2714	.
O	2714	2717	gov
O	2718	2730	NCT004174248
O	2730	2731	;
O	2732	2737	https
O	2737	2738	:
O	2738	2739	/
O	2739	2740	/
O	2740	2754	clinicaltrials
O	2754	2755	.
O	2755	2758	gov
O	2758	2759	/
O	2759	2762	ct2
O	2762	2763	/
O	2763	2767	show
O	2767	2768	/
O	2768	2779	NCT04174248
O	2779	2780	.
